![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright Tamez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. An Erythrocyte Vesicle Protein Exported by the Malaria Parasite Promotes Tubovesicular Lipid Import from the Host Cell Surface 1Department of Pathology, Feinberg School of Medicine, Northwestern University Chicago, Illinois, United States of America 2Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University Chicago, Illinois, United States of America 3Allegheny General Hospital, Allegheny-Singer Research Institute, Center for Genomic Sciences, Pittsburgh, Pennsylvania, United States of America 4Department of Molecular Biology, Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey, United States of America 5Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, United States of America James Kazura, Editor Case Western Reserve University, United States of America * E-mail: k-haldar/at/northwestern.edu ¤Current address: Global Health Infectious Diseases Research (GHIDR) Program, University of South Florida, College of Public Health, Tampa, Florida, United States of America Designed the research: PAT KH. Analyzed data and wrote the paper: PAT KH. Performed microarray analyses, experiments, hybridizations, production of antibodies to N and C termini of PFD0495c, development of the transgenic line and its functional characterization by western blots, fluorescence microscopy, growth assays and in resealed ghosts: PAT. Conducted immunolocalization experiments of endogenous PFD0495c/EVP-1 and FM4-64 experiments: SB. Contributed new reagents: CvO BB JHA. Determined the sites of piggybac insertion: BB. Helped with sequence annotation: NLH. Performed the duplicate array hybridizations: ML. Received November 16, 2007; Accepted July 10, 2008. Abstract Plasmodium falciparum is the protozoan parasite that causes the most virulent of human malarias. The blood stage parasites export several hundred proteins into their host erythrocyte that underlie modifications linked to major pathologies of the disease and parasite survival in the blood. Unfortunately, most are ‘hypothetical’ proteins of unknown function, and those that are essential for parasitization of the erythrocyte cannot be ‘knocked out’. Here, we combined bioinformatics and genome-wide expression analyses with a new series of transgenic and cellular assays to show for the first time in malaria parasites that microarray read out from a chemical perturbation can have predictive value. We thereby identified and characterized an exported P. falciparum protein resident in a new vesicular compartment induced by the parasite in the erythrocyte. This protein, named Erythrocyte Vesicle Protein 1 (EVP1), shows novel dynamics of distribution in the parasite and intraerythrocytic membranes. Evidence is presented that its expression results in a change in TVN-mediated lipid import at the host membrane and that it is required for intracellular parasite growth, but not invasion. This exported protein appears to be needed for the maintenance of an essential tubovesicular nutrient import pathway induced by the pathogen in the host cell. Our approach may be generalized to the analysis of hundreds of ‘hypothetical’ P. falciparum proteins to understand their role in parasite entry and/or growth in erythrocytes as well as phenotypic contributions to either antigen export or tubovesicular import. By functionally validating these unknowns, one may identify new targets in host–microbial interactions for prophylaxis against this major human pathogen. Author Summary Plasmodium falciparum, the most virulent form of human malaria, causes disease when it invades a red blood cell. It sends proteins beyond its borders into the host, changing the red cell to make it a suitable environment to live in and to interact with the host immune system. Recent findings have predicted that hundreds of parasite proteins are released into the host red cell. However, most of these proteins have no known function. One major challenge is to understand what role these proteins play in parasite growth in order to design drugs or vaccines that block protein function. In this study, we designed a strategy to characterize ‘hypothetical’ proteins and use one as an example to illustrate the principle. We show that this protein resides within a novel compartment within the red cell and changes lipid transport at the host surface to stabilize a major nutrient pathway formed within the human cell. In principle, this strategy is applicable in determining the functions of other parasite genes involved in pathogen–host interactions. Introduction Blood stage infection by Plasmodium falciparum causes all of the disease symptoms and pathologies associated with malaria [1],[2] and begins when the extracellular ‘merozoite’ stage invades the mature erythrocyte. The newly formed intracellular ‘ring’ stage parasite is surrounded by a parasitophorous vacuolar membrane (PVM). As ring parasites mature to the ‘trophozoite’ stage, a tubovesicular network (TVN) buds as a series of interconnected vesicles from the PVM into the host erythrocyte to support import of nutrients as well raft proteins and lipids from the erythrocyte membrane [3],[4]. In addition to creating an import pathway and modifying permeation properties of the host membrane by a non-selective ion channel [5], the parasite alters its host in other ways. Increasing adhesiveness of the infected erythrocyte to endothelial cells allows the parasite to escape splenic destruction [6]. Stabilizing the erythrocyte cytoskeleton also protects against the damaging effects of febrile temperatures [7]. Several hundred parasite proteins predicted to be exported to the erythrocyte [8]–[10] presumably underlie the molecular basis of erythrocyte remodeling in order to make this host cell a suitable environment for intracellular parasite growth. Most are ascribed as ‘hypothetical’ proteins, and since genetic manipulation of this parasite remains limited, their role in infection is poorly understood. Nonetheless, non-essential proteins involved in antigen export to the erythrocyte as well as stabilization/destabilization of the erythrocyte cytoskeleton [7],[11] have been increasingly amenable to study. Prevalent molecular and genetic analyses have thus assessed their contribution to antigen export and/or function at the host membrane [12],[13]. In contrast very little is understood at the molecular/genetic level about the biogenesis of the TVN since genes underlying it are expected to be essential for infection and cannot be knocked out. At the time of its discovery, the biosynthesis of sphingomyelin was recognized to be an import feature of the TVN. Inhibiting a parasite sphingomyelin synthase activity exported to the erythrocyte [14] with sphingolipid analogues (such as dl-threo-1-phenyl-2-palmitoyl-3-morpholino-1-propanol; PPMP) [4] blocked formation of TVN tubules and their import functions. By blocking the TVN, PPMP does not immediately kill the parasite but rather arrests its development, an effect that can be completely reversed by washing out the drug even after 24 h. To facilitate the identification of genes that regulate the TVN, we examined the global transcriptional profile of infected erythrocytes in response to PPMP treatment. By intersecting these genes with those predicted to be exported to the erythrocyte and conserved across the genus Plasmodium [10],[15], we identify a protein that is apparently necessary for TVN assembly and stimulates endovesiculation from the erythrocyte membrane. These data suggest that although transcription by the malaria parasite is thought to be largely ‘hard-wired’, a block in erythrocyte remodeling induces a measurable transcriptional response and reveals parasite proteins that function in novel pathogenic mechanisms of nutrient acquisition in the host cell. Results To identify proteins linked to the TVN, we examined transcriptional changes induced in P. falciparum genes in response to treatment of infected erythrocytes with PPMP for 24 h. We compared PPMP-treated parasites to rings (the starting population) and trophozoites (the mock control) (Figure 1A
Of the 81 genes that changed with PPMP treatment, 39 were up-regulated and 42 down-regulated. We then limited the list by focusing on gene products that met two criteria: those that contained a host-targeting signal and were conserved between human and rodent malaria parasites (Figure S1, [8],[15]). We reasoned that these proteins were likely to reflect essential functions of parasite remodeling preserved throughout the genus. An intersection of these genes with those that show PPMP-induced changes in transcriptional profiles relative to the trophozoite stage yielded two conserved genes (PFD0495c and PFC0435w; Figure 1D To establish export of PFD0495c to the erythrocyte we utilized piggyBac (a type II transposon element from the lepidopteran Trichoplusia ni, that specifically excises and integrates at TTAA target sites) to randomly insert a tagged copy of pfd0495c-gfp in the genome [15],[16] (also shown for reference in Figure 2A
Examination of pfd0495c-gfp parasites by fluorescence microscopy revealed fluorescence at the erythrocyte membrane (Figure 2A
Transcription of pfd0495c-gfp is driven by the cam promoter, which is largely constitutive with peak transcription at the trophozoite and schizont stages [17],[18]. In contrast endogenous pfd0495c shows peak transcription at the schizont and early ring stages, although transcriptional activity remains detectable in late rings and trophozoites [17],[18] albeit at lower levels. We examined protein levels of PFD0495c in both 3D7 wildtype and transgenic parasites to determine how these lines differed in protein expression and their response to PPMP treatment. Although antibodies developed to the C-terminus of PFD0495c were clearly specific, they were not of sufficient titer to detect varying levels of protein throughout the asexual life cycle (not shown). We therefore developed high titer antibodies to the N-terminal repeat region of PFD0495c which also recognized one major protein band of the expected size of ~130 kDa in 3D7 late stage schizonts (Figure 3C The lack of a detectable protein product for endogenous pfd0495c in ring stages (Figure 3C Western blots in Figure 3
Next we were interested in determining whether PFD0495c is essential for TVN development. It is one of only 11 conserved, exported proteins encoded by syntenic genes in Plasmodium genomes. We attempted to delete nine of the 11 genes in P. berghei but were unsuccessful [15], suggesting that they may be essential genes. Thus independent evidence that PFD0495c contributed to the TVN formation/function would likely not be obtained by undertaking knock out experiments. We therefore chose an alternate approach of loading cargo into resealed erythrocytes to monitor for effects on parasite invasion or growth. The principle is that by loading dominant-negative recombinant fragments of the protein of interest into ghosted erythrocytes and infecting, endogenous protein interactions will be disrupted, which will have effects on parasite fitness. Only proteins that function within the erythrocyte cytosol may be considered, and the domains that function within the erythrocyte cytosol must be identified. This approach has been employed to identify known cytoplasmic determinants of both host and parasite origin needed for parasite invasion [7],[21] and has recently been optimized to support parasite invasion and growth to the same degree as normal erythrocytes [21]. To extend it to investigation of a protein of unknown function, we needed to identify which domain of the protein was exposed to the erythrocyte cytoplasm. As shown in Figure 5
To assess the functional importance of this domain during infection, we introduced 50 µM of a recombinant form of the C-terminal region of PFD0495c fused to glutathione S-transferase (GST-PFD0495cCterm; Figure S6) into the cytoplasm of resealed erythrocyte ghosts [21] (Figure 5C To investigate whether inhibition of trophozoite maturation could be specifically linked to intraerythrocytic transport functions, we reduced the concentration of GST-PFD0495cCterm in the erythrocyte cytoplasm to 10 µM. This allowed growth of enlarged trophozoites (see Figure 6
Discussion The first parasite determinant (a sphingolipid synthase activity) known to be important to the TVN was identified in the mid-nineties concomitant with the identification of this organelle [23]. Despite steady progress on characterizing the function of the TVN in the import of nutrients, lipids and host raft proteins [3],[4],[24], the contribution of additional parasite proteins to the network has remained elusive. Almost fifteen years after the discovery of the synthase we identified two candidate genes PFC0435w and PFD0495c that may be linked to the TVN. PFC0435w is shown to be a TVN junction protein [15] while PFD0495c defines a novel vesicular membrane compartment in the infected host cell (and we therefore name it erythrocyte vesicle protein 1 or EVP1) that shifts lipid dynamics within the host cell. The discoveries of EVP1 as well as TVN Junction Protein 1 (TVN-JP1; [15]) well over a decade after the identification of the sphingolipid synthase was achieved by integrating expression profiling with additional rapid genetic and functional assays. The finding that microarray outputs of malaria parasites may be predictive for function is somewhat contrary to the idea that has emerged from prior work that the parasite is hard-wired and does not respond to environmental cues [25]. One reason for the discrepancy may be that most studies investigate transcriptional change in response to drugs that kill the parasite. The secondary effects of death may confound analysis by generating noise that is difficult to filter out. In contrast PPMP treatments for periods used in these studies (24 h) arrest parasites at the early trophozoite stage but do not kill them. Additionally, because secretome gene products are at the host-pathogen interface and function between the intracellular parasite and the blood, they may be more sensitive to environmental cues. The fact that PFD0495c protein levels did not increase concomitantly with PPMP up-regulation of transcription may be due to several reasons. One explanation for this discrepancy is that the increase in transcript levels is too modest to be able to detect an increase in protein. A second possibility is that the high molecular weight oligomeric forms inhibit detection of protein at the correct molecular weight. A third alternative is that pfd0495c messenger RNA is degraded faster than protein can be made. In fact, transcription of EVP-1 is detected throughout the lifecycle, dipping during the late trophozoite stage and peaking at late schizogony (Figure 1E Notably, although pfd0495c is up-regulated with PPMP treatment, schizont stage genes, such as MSP-1, are not. This suggests that our treated parasite population is well synchronized and not contaminated with parasites that are beyond the PPMP block. In fact, MSP-1 is down-regulated with PPMP treatment indicating that the parasites do not progress through schizogony. Although PPMP-induced changes are relatively modest, they were predictive for TVN function of our candidate genes. The use of microarrays as predictive tools is enormously beneficial in human malaria parasites that are difficult to manipulate genetically. Our studies provide a road map to rapidly move from in silico predictions to initial annotation of these proteins in infection (Figure S7). piggyBac provides a rapid system to produce transgenic parasites with which to examine changes in intraerythrocytic transport functions in antigen export and lipid/nutrient import. Producing these parasites with such speed enables detailed characterization of sites of integration as well as other characteristics to ensure that they are suitable for analysis of a given transport phenotype. Finally for genes likely to be essential, our study provides an alternative approach to assessing functional importance of their gene products for invasion or intracellular parasite growth. This method relies on the ability to disrupt endogenous protein interactions by loading dominant-negative recombinant forms into resealed erythrocyte ghosts. The use of small peptide domains (of 30–90 amino acids) in GST fusions circumvents difficulties in expressing recombinant forms of P. falciparum proteins without codon optimization and is consistent with published data that small protein domains of P. falciparum are efficiently expressed as soluble protein in E. coli [27]. Larger, more insoluble domains can be truncated into smaller domains to identify specific inhibitory portions. Truncations in conjunction with secondary structure prediction and production of overlapping fragments can assist in production of optimal fragments (Murphy and Haldar, unpublished). In principle this strategy may be applicable to over 50% of parasite genes involved in pathogen-host interactions where over half have unknown functions [28]. Our studies of EVP1 suggest that its associated vesicles are distinct from Maurer's clefts known to function in protein export to the erythrocyte. The distribution of EVP1 is also distinct from PVM proteins such as PfEXP1 and ETRAMPs that are seen in membrane extensions off the PVM. In this context the intraerythrocytic compartment to which EVP1 localizes may define a hitherto poorly defined membrane intermediate in the infected erythrocyte. Our initial localization studies suggest the bulk of these vesicles are not at the erythrocyte periphery, although the gene has an elevated rate of polymorphisms [29]–[31], suggesting it is under host pressure. Further expression of a second copy of the gene can change the dynamics of localization, suggesting function in a novel endovesiculation pathway or transbilayer lipid movement at the infected erythrocyte membrane. We speculate that the physiological substrate of EVP-1 could be a variety of lipids, including sphingolipids, although a definitive substrate remains to be identified. Nevertheless changing lipid import properties at the infected erythrocyte membrane does not circumvent the block induced by PPMP (although the parasites are arrested at a state of two rather than one nucleus), suggesting additional factors also contribute to proper TVN and membrane import. We can begin to piece together the sequence of events that build and maintain the TVN. Sphingomyelin synthesis is a critical early event. If its activity is inhibited early in the asexual cycle, then the TVN is not properly assembled and nutrients are not imported. Several pieces of evidence support the idea that EVP1 is required later in the cycle. The predominant form of the protein is detected in later stages and not in ring stages. The resealed ghosted erythrocyte experiments demonstrate that the dominant-negative GST recombinant form of the C-terminus inhibits parasite maturation not invasion. Finally the transgenic line retains sensitivity to PPMP but has altered TVN properties. Since the TVN is assembled from the late ring stage to early schizogony, the data unexpectedly reveal that vesicular import from the erythrocyte membrane at its later stages of assembly may be important for the maintenance of this network. Hence the TVN remains a dynamic structure even though its tubules appear as relatively immobile structures in the erythrocyte cytoplasm. The facts that EVP1 is important for the development of the TVN and is also a member of a conserved set of exported proteins suggest that the encoding gene pfd0495c is essential for blood stage infection. Finally, although essential genes cannot yet be knocked out in blood stage Plasmodium, we nonetheless show that this does not preclude insight into the complexity of vesicular intermediates and membrane dynamics utilized by a pathogen to develop an essential nutrient transport pathway in its mammalian host. Materials and Methods Transcriptional response of Plasmodium falciparum-infected erythrocytes to PPMP treatment Ring stage parasites were treated with either 5 µM dl-threo-PPMP or vehicle ([ethanol]f = 0.01%) for 24 hr and were harvested for RNA isolation. Untreated ring stage parasites were also harvested. The experimental design served to compare PPMP- to either mock-treated or ring stage transcripts. This first biological replicate compared treated to control directly, whereas the second biological experiment compared each sample (treated or control) to a reference sample, pooled RNA. RNA was isolated according to Invitrogen (Carlsbad, CA) protocols using Trizol. First strand cDNA synthesis and hybridizations were performed according to previous protocols [18]. Microarray slides were scanned using GenePix 4000B Scanner and analyzed with GenePix Pro 4.1. The statistical program R with the add-in package SMA (from Terry Speed's group at http://www.stat.berkeley.edu/7Eterry/zarray/Software/smacode.html) was used to normalize data [32],[33] for the first biological experiment. Features with a log odds ratio above zero were considered. Only high quality features and those with signal two standard deviations above background were analyzed for both biological replicates, leaving 4580 elements from a total of 8088 oligos for the first and 6221 elements from a total of 7283 oligos for the second experiment.Quantitative RT-PCR Quantitative PCR [34] was used to confirm the array results. Parasites were synchronized by successive rounds of percoll and sorbitol. Ring stage parasites were treated with either 5 µM dl-threo-PPMP or vehicle (ethanol = 0.01%) for 3, 6, 12, and 24 h. RNA was isolated using Trizol (Invitrogen) and treated with DNAse (Promega) according to manufacturer's recommendations. Integrity of the RNA was confirmed with the 2100 Bioanalyzer (Agilent). First strand cDNA synthesis was initiated by priming 5 µg RNA with 40 µg/mL oligo(dT)12–18 at 65°C for 5 min then incubating reaction with 0.5 mM dNTPs and 200 U SuperScript reverse transcriptase (Invitrogen) for 60 min at 42°C. The reaction was inactivated by heating to 70°C for 15 min. Each qRT-PCR reaction, done in triplicate, contained 1 ng cDNA, 2 µM primers (forward 5′-GCTCTTTCCATAAATACTGTATT-3′, reverse 5′-ATGGCCAAACAACATCA-3′) and SYBR green chemistry (Applied Biosystems) and was done using the 7900HT ABI system according to ABI protocols. Amplification of P. falciparum 18S ribosomal RNA (gi 160642), an endogenous control, was done in parallel (forward 5′-ACAATTGGAGGGCAAGT-3′, reverse 5′-TTGGAGCTGGAATTACC-3′) to standardize the amount of sample in each well. A control reaction that did not receive reverse transcriptase was included to account for non-specific amplification due to contaminating DNA. Relative quantification was performed using the comparative method, whereby the amount of pfd0495c was normalized to the endogenous control 18S rRNA. Control samples receiving only vehicle were used to calibrate each PPMP sample at that time point.Transfection using PiggyBac type II transposable element Full length pfd0495c (gi 23510091) was amplified from gDNA using the oligos 5′-aaaaagcaggcttcgaaggagatagaaccatgATGTATAAGAAATGTTTCATTTTATATCCTATCTTTTTTC-3′ and 5′-agaaagctgggtcTCATCTGTCGTCGGAACGGAAGGAATC-3′ (partial attB sites in lower case). Cloning with the Gateway system was according to Invitrogen protocols. To make the destination vector, the dhfr gene with control regions and pfcam promoter and pfhsp86 3′ UTR was ligated to pXL-BAC-HH [16], which contained OriC, the ampicilin resistance gene and the IR and TR sequences. The transposase plasmid was described previously [16]. Both integration and transposase plasmids (100 µg each) were simultaneously electroporated into erythrocytes. Forty-eight hours after transfection, selection with 2.5 nM WR99210 was initiated. After 11 days of selection, GFP-expressing parasites were detected. GFP-expressing parasites were then cloned by limiting dilution at 0.2 parasites/well in a 96-well plate. Fresh media and 1% hematocrit were added at days 6 and 13, and at day 17 parasitemia of each well was determined by examining thick smears stained by Giemsa. PiggyBac insertion site analysis To confirm integration into the genome, Southern analysis was performed, digesting 2 µg DNA (either gDNA or plasmid) with 10 units of either BglII or EcoRV. The coding sequence of hdhfr labeled with 32P was used as a probe. No episomes were maintained, and only one insertion was detected for both clones 1 and 2 of PFD0495c-GFP. piggyBac insertion sites in the genome were identified by using an adaptor-ligation-mediated PCR method (Balu and Adams, unpublished data). Briefly, Rsa I digested genomic DNA was ligated to compatible adaptors and used in a PCR reaction with an internal piggyBac primer and a primer in the adaptor. The PCR products obtained were then directly sequenced to identify the insertion sites. Insertion of the expression cassette within the piggyBac Inverted Terminal Repeats occurred in chromosome 12 between loci PFL1425w (T complex protein) and PFL1430c (hypothetical protein). Growth of PFD0495c-GFP transgenic line and 3D7 To compare growth of pfd0495c-gfp expressing parasites to 3D7, Giemsa-stained blood smears were counted to determine numbers of rings, trophozoites and schizonts. Percoll-purified schizonts were mixed with erythrocytes at ~2% parasitemia in 2% hematocrit. Blood smears were made every 24 hr from day 0 to 4, and medium was changed daily. At day 2 ring stage parasites were subcultured to 3% parasitemia. The experiment was conducted in duplicate, and the counter was blinded to sample identity. There were no detectable differences in growth among the uncloned population, clone 1 PFD0495c-GFP, and 3D7 parasites. Antibodies to PFD0495c In rabbits, anti-peptide antibodies were raised against the C-terminus of PFD0495c: peptide LKFQHDQEFLNYFKRYQDFN (NeoMPS, San Diego, CA). Lysates of 1×106 parasite or uninfected erythrocyte equivalents were analyzed by SDS-PAGE and probed. Antibodies reacted with a single band only in parasite lysates. Anti-peptide antibodies were raised against the N-terminal repeat region of PFD0495c: peptide DDNVNHTNDDKVNHTN (Affinity Bioreagents, Golden, CO). Infected cell pellets were lysed in hypotonic buffer (10 mM Tris, 2 mM EDTA, 2 mM EGTA, pH 7.4) and centrifuged at 100,000 × g to pellet membranes. Pellet fractions of 1×107 parasite equivalents were separated by SDS-PAGE and probed with indicated antibodies. Immunofluorescence To determine localization of endogenous PFD0495c, 3D7 trophozoites were harvested and probed with antibodies to PFD0495c and Skeleton Binding Protein (SBP1) and appropriate secondary antibodies conjugated to FITC or rhodamine. Nuclei were stained with 10 µg/mL Hoechst 33342. Images were captured using DeltaVision Deconvolution microscopy as described [3]. A high-resolution 3-D image was captured with an Olympus IX inverted fluorescence microscope and a Photometrix cooled CCD camera (CH350/LCCD) driven by DeltaVision software (softWoRx) from Applied Precision Inc (Seattle, WA). Twelve to fifteen 200 nm optical sections were taken through the depth of the cell, and DeltaVision software was used to deconvolve images and reconstruct a 3-D view. To determine effects on export in resealed erythrocytes, ghosts that were infected with 3D7 were probed with antibodies to HRPII (Santa Cruz) and MSP1 (MR4) and appropriate secondary antibodies conjugated to FITC or rhodamine. Nuclei were stained with 10 µg/mL Hoechst 33342. Cells were viewed using DeltaVision Deconvolution microscopy as described [3]. Monitoring endocytic lipid import with the lipid marker FM4-64 FM4-64 (N-(3-triethylammoniumpropyl)-4-(6-(4-(diethylamino)phenyl)hexatrienyl)pyridinium dibromide) is a fluorescent lipid marker that has been used to study endocytosis in eukaryotic cells [19]. To visualize active uptake of FM4-64 from the erythrocyte plasma membrane during intraerythrocytic growth, trophozoite stage parasites expressing either PfHRPII-GFP or PFD0495c-GFP were incubated in the absence or presence of 5 µM dl-threo-PPMP for 30 min at 37°C. Infected erythrocytes were washed three times in PBS then stained with 16 µM FM4-64 for 30 min at 37°C. Nuclei were stained with 10 µg/mL Hoechst 33342, and cells were washed with PBS three times. Cells were imaged live with DeltaVision Deconvolution microscopy [3]. Visualization of tubo-vesicular network by BODIPY-Texas Red C5 Ceramide staining To visualize TVN membranes, erythrocytes or ghosts infected with indicated P. falciparum strain were washed free of serum and stained with 2.5 µM BODIPY-Texas Red C5 ceramide (N-((4-(4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)sphingosine, Invitrogen) for 15 min at 37°C. Nuclei were stained with 10 µg/mL Hoechst 33342. The cells were washed in RPMI 1640 three times and viewed live by DeltaVision Deconvolution microscopy as described [3]. Determination of PFD0495c-GFP topology using Tetanolysin Selective permeabilization of the erythrocyte plasma membrane using tetanolysin was performed according to published protocols [35]. Erythrocytes infected with PFD0495c-GFP expressing parasites (38–42-h post-invasion) were probed with antibodies to GFP (Molecular Probes) or MSP1 (Anthony Holder) and appropriate secondary antibodies conjugated to rhodamine or Cy-5. Cells were viewed using DeltaVision Deconvolution microscopy as described [3]. Expression of GST fusions To produce recombinant GST-PFD0495c cargo, the C-terminus (amino acids 795 to 833) was amplified using oligonucleotides 5′-aaaaagcaggcttcGATTTAGATATTGATGATACTTTAAAGTTTCAGCATGATCAA-3′ and 5′-agaaagctgggtcTCATCTGTCGTCGGAACGGAAGGAATC-3′ (partial attB sites in lowercase). To produce GST-Repeat cargo, the repeat region was amplified using oligonucleotides 5′- aaaaagcaggcttcGATGATGTGGTGAGAAATATTAACGATGATGTG-3′ and 5′ agaaagctgggtcTCAACTATTATTAGTTTTTATATCACCTGCATTATTCTTTTTATCATTATA-3′. To produce GST-SBP cargo, the C-terminus of SBP (amino acids 239 to 337) was amplified using oligos 5′-aaaaagcaggcttcGGAAAAAGAAAAGGATATTACCTAGCAAAAAAAC-3′ and 5′-agaaagctgggtcTTAAGGTTTCTCTAGCAACTGTTTTTGTTGTGG-3′. Cloning into the Gateway system was performed with pDEST15 (Invitrogen). Expression of recombinant fusions was induced with 1 mM Isopropyl-(beta)-D-thiogalactopyranoside (IPTG) (Eppendorf) for 2 h at 37°C. Protein purification was performed with glutathione resin (Clontech) in non-denaturing buffer containing 50 mM Tris, pH 8, 50 mM NaCl, 5 mM EDTA. Loading GST-fusions into erythrocyte cytoplasm and subsequent infection by Plasmodium falciparum Erythrocytes were loaded with GST cargo and resealed according to previous protocols [21]. Schizonts were percoll-purified to >95% purity and mixed with loaded ghosts at 2% parasitemia. Blood smears were made from a hematocrit of 20–30% and stained with Giemsa for 7 minutes, rather than 2 min, in order to better visualize ghosts. Numbers of rings, trophozoites and schizonts were enumerated by a counter who was blinded to sample identity. Parasite morphology was monitored for any differences. Images of blood smears were taken by light microscopy with a Zeiss Axioskop upright microscope and Nuance spectral camera/un-mixing system (Cambridge Research and Instrumentation). Protocol S1 Supplementary Materials/Methods and References (0.05 MB DOC) Click here for additional data file.(51K, doc) Figure S1 List of genes containing a host-targeting motif conserved between P. falciparum and P. berghei [3]. (0.38 MB TIF) Click here for additional data file.(367K, tif) Figure S3 Comparative analyses of effects of PPMP on maturation of parent 3D7 and clones 1 and 2 expressing PFD0495c-GFP. (2.89 MB TIF) Click here for additional data file.(2.7M, tif) Figure S4 Detailed analysis of microarray and protein expression data of PFD0495c. (4.08 MB TIF) Click here for additional data file.(3.8M, tif) Figure S5 Quantification of parasite-induced structures within the erythrocyte cytosol in 3D7 wild-type and PFD0495c-GFP transgenic parasites treated with 5 µM PPMP for 24 h. (1.33 MB TIF) Click here for additional data file.(1.2M, tif) Figure S6 Coomassie-stained SDS-PAGE gels of GST-fusions of C-terminal domains of PFD0495c and SBP, and N-terminal PFD0495c repeat region expressed in E. coli (>90% purity) purified under native conditions. (1.46 MB TIF) Click here for additional data file.(1.3M, tif) Figure S7 Flow diagram of strategy to identify and functionally characterize P. falciparum proteins exported to the erythrocyte and required for blood stage parasite infection. (0.99 MB TIF) Click here for additional data file.(965K, tif) Acknowledgments We thank Drs. Joseph DeRisi and Pradip Rathod for microarray chips and Dr. Athanasios Lykidis for technical, microarray expertise. PlasmoDB (http://www.plasmodb.org) provided sequence information and transcriptional plots. Footnotes The authors have declared that no competing interests exist. The work in this study was supported by grants to KH (NIH: R01AI39071, R01HL69630, P01 HL 078826, UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)), to JHA (NIH: RO1 AI033656, R21 AI AI070888 and Burroughs Wellcome Fund grant no. 1006227), to ML (Princeton University), and to PAT (Institutional National Research Service Award (Dept.Microbiology-Immunology T32 AI007476) and the American Heart Association (0425607Z)). References 1. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002;415:673–679. [PubMed] 2. Haldar K, Murphy SC, Milner DA, Taylor TE. Malaria: Mechanisms of Erythrocytic Infection and Pathological Correlates of Severe Disease. Annu Rev Pathol. 2007;2:217–249. [PubMed] 3. Lauer S, VanWye J, Harrison T, McManus H, Samuel BU, et al. Vacuolar uptake of host components, and a role for cholesterol and sphingomyelin in malarial infection. Embo J. 2000;19:3556–3564. [PubMed] 4. Lauer SA, Rathod PK, Ghori N, Haldar K. A membrane network for nutrient import in red cells infected with the malaria parasite. Science. 1997;276:1122–1125. [PubMed] 5. Desai SA, Bezrukov SM, Zimmerberg J. A voltage-dependent channel involved in nutrient uptake by red blood cells infected with the malaria parasite. Nature. 2000;406:1001–1005. [PubMed] 6. Craig A, Scherf A. Molecules on the surface of the Plasmodium falciparum infected erythrocyte and their role in malaria pathogenesis and immune evasion. Mol Biochem Parasitol. 2001;115:129–143. [PubMed] 7. Pei X, Guo X, Coppel R, Bhattacharjee S, Haldar K, et al. The ring-infected erythrocyte surface antigen (RESA) of Plasmodium falciparum stabilizes spectrin tetramers and suppresses further invasion. Blood. 2007;110:1036–1042. [PubMed] 8. Hiller NL, Bhattacharjee S, van Ooij C, Liolios K, Harrison T, et al. A host-targeting signal in virulence proteins reveals a secretome in malarial infection. Science. 2004;306:1934–1937. [PubMed] 9. Marti M, Good RT, Rug M, Knuepfer E, Cowman AF. Targeting malaria virulence and remodeling proteins to the host erythrocyte. Science. 2004;306:1930–1933. [PubMed] 10. Sargeant TJ, Marti M, Caler E, Carlton JM, Simpson K, et al. Lineage-specific expansion of proteins exported to erythrocytes in malaria parasites. Genome Biol. 2006;7:R12. [PubMed] 11. Pei X, Guo X, Coppel R, Mohandas N, An X. Plasmodium falciparum erythrocyte membrane protein 3 (PfEMP3) destabilizes erythrocyte membrane skeleton. J Biol Chem. 2007;282:26754–26758. [PubMed] 12. Cooke BM, Buckingham DW, Glenister FK, Fernandez KM, Bannister LH, et al. A Maurer's cleft-associated protein is essential for expression of the major malaria virulence antigen on the surface of infected red blood cells. J Cell Biol. 2006;172:899–908. [PubMed] 13. Maier AG, Rug M, O'Neill MT, Beeson JG, Marti M, et al. Skeleton-binding protein 1 functions at the parasitophorous vacuole membrane to traffic PfEMP1 to the Plasmodium falciparum-infected erythrocyte surface. Blood. 2007;109:1289–1297. [PubMed] 14. Lauer SA, Ghori N, Haldar K. Sphingolipid synthesis as a target for chemotherapy against malaria parasites. Proc Natl Acad Sci U S A. 1995;92:9181–9185. [PubMed] 15. van Ooij C, Tamez P, Bhattacharjee S, Hiller NL, Harrison T, et al. The malaria secretome: from algorithms to essential function in blood stage infection. PLoS Pathog. 2008;4:e1000084. doi:10.1371/journal.ppat.1000084. [PubMed] 16. Balu B, Shoue DA, Fraser MJ, Jr, Adams JH. High-efficiency transformation of Plasmodium falciparum by the lepidopteran transposable element piggyBac. Proc Natl Acad Sci U S A. 2005;102:16391–16396. [PubMed] 17. Bahl A, Brunk B, Crabtree J, Fraunholz MJ, Gajria B, et al. PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data. Nucleic Acids Res. 2003;31:212–215. [PubMed] 18. Bozdech Z, Zhu J, Joachimiak MP, Cohen FE, Pulliam B, et al. Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. Genome Biol. 2003;4:R9. [PubMed] 19. Vida TA, Emr SD. A new vital stain for visualizing vacuolar membrane dynamics and endocytosis in yeast. J Cell Biol. 1995;128:779–792. [PubMed] 20. Bhattacharjee S, van Ooij C, Balu B, Adams JH, Haldar K. Maurer's clefts of Plasmodium falciparum are secretory organelles that concentrate virulence protein reporters for delivery to the host erythrocyte. Blood. 2008;111:2418–2426. [PubMed] 21. Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, et al. Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med. 2006;3:e528. doi:10.1371/journal.pmed.0030528. [PubMed] 22. Spielmann T, Gardiner DL, Beck HP, Trenholme KR, Kemp DJ. Organization of ETRAMPs and EXP-1 at the parasite-host cell interface of malaria parasites. Mol Microbiol. 2006;59:779–794. [PubMed] 23. Elmendorf HG, Haldar K. Plasmodium falciparum exports the Golgi marker sphingomyelin synthase into a tubovesicular network in the cytoplasm of mature erythrocytes. J Cell Biol. 1994;124:449–462. [PubMed] 24. Murphy SC, Samuel BU, Harrison T, Speicher KD, Speicher DW, et al. Erythrocyte detergent-resistant membrane proteins: their characterization and selective uptake during malarial infection. Blood. 2004;103:1920–1928. [PubMed] 25. Gunasekera AM, Myrick A, Le Roch K, Winzeler E, Wirth DF. Plasmodium falciparum: genome wide perturbations in transcript profiles among mixed stage cultures after chloroquine treatment. Exp Parasitol. 2007;117:87–92. [PubMed] 26. Shock JL, Fischer KF, DeRisi JL. Whole-genome analysis of mRNA decay in Plasmodium falciparum reveals a global lengthening of mRNA half-life during the intra-erythrocytic development cycle. Genome Biol. 2007;8:R134. [PubMed] 27. Mehlin C, Boni E, Buckner FS, Engel L, Feist T, et al. Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol. 2006;148:144–160. [PubMed] 28. Gardner MJ, Hall N, Fung E, White O, Berriman M, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002;419:498–511. [PubMed] 29. Jeffares DC, Pain A, Berry A, Cox AV, Stalker J, et al. Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat Genet. 2007;39:120–125. [PubMed] 30. Mu J, Awadalla P, Duan J, McGee KM, Keebler J, et al. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat Genet. 2007;39:126–130. [PubMed] 31. Volkman SK, Sabeti PC, DeCaprio D, Neafsey DE, Schaffner SF, et al. A genome-wide map of diversity in Plasmodium falciparum. Nat Genet. 2007;39:113–119. [PubMed] 32. Lonnstedt I, Speed TP. Replicated microarray data. Statistica Sinica. 2002;12:31–46. 33. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30:e15. [PubMed] 34. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y). 1993;11:1026–1030. [PubMed] 35. Hiller NL, Akompong T, Morrow JS, Holder AA, Haldar K. Identification of a stomatin orthologue in vacuoles induced in human erythrocytes by malaria parasites. A role for microbial raft proteins in apicomplexan vacuole biogenesis. J Biol Chem. 2003;278:48413–48421. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Nature. 2002 Feb 7; 415(6872):673-9.
[Nature. 2002]Annu Rev Pathol. 2007; 2():217-49.
[Annu Rev Pathol. 2007]EMBO J. 2000 Jul 17; 19(14):3556-64.
[EMBO J. 2000]Science. 1997 May 16; 276(5315):1122-5.
[Science. 1997]Nature. 2000 Aug 31; 406(6799):1001-5.
[Nature. 2000]Science. 2004 Dec 10; 306(5703):1934-7.
[Science. 2004]Genome Biol. 2006; 7(2):R12.
[Genome Biol. 2006]Blood. 2007 Aug 1; 110(3):1036-42.
[Blood. 2007]J Biol Chem. 2007 Sep 14; 282(37):26754-8.
[J Biol Chem. 2007]J Cell Biol. 2006 Mar 13; 172(6):899-908.
[J Cell Biol. 2006]Proc Natl Acad Sci U S A. 1995 Sep 26; 92(20):9181-5.
[Proc Natl Acad Sci U S A. 1995]Science. 1997 May 16; 276(5315):1122-5.
[Science. 1997]Genome Biol. 2006; 7(2):R12.
[Genome Biol. 2006]PLoS Pathog. 2008 Jun 13; 4(6):e1000084.
[PLoS Pathog. 2008]Science. 1997 May 16; 276(5315):1122-5.
[Science. 1997]Nucleic Acids Res. 2002 Feb 15; 30(4):e15.
[Nucleic Acids Res. 2002]Science. 2004 Dec 10; 306(5703):1934-7.
[Science. 2004]Genome Biol. 2006; 7(2):R12.
[Genome Biol. 2006]PLoS Pathog. 2008 Jun 13; 4(6):e1000084.
[PLoS Pathog. 2008]Science. 2004 Dec 10; 306(5703):1934-7.
[Science. 2004]PLoS Pathog. 2008 Jun 13; 4(6):e1000084.
[PLoS Pathog. 2008]PLoS Pathog. 2008 Jun 13; 4(6):e1000084.
[PLoS Pathog. 2008]Proc Natl Acad Sci U S A. 2005 Nov 8; 102(45):16391-6.
[Proc Natl Acad Sci U S A. 2005]Nucleic Acids Res. 2003 Jan 1; 31(1):212-5.
[Nucleic Acids Res. 2003]Genome Biol. 2003; 4(2):R9.
[Genome Biol. 2003]EMBO J. 2000 Jul 17; 19(14):3556-64.
[EMBO J. 2000]J Cell Biol. 1995 Mar; 128(5):779-92.
[J Cell Biol. 1995]Blood. 2008 Feb 15; 111(4):2418-26.
[Blood. 2008]PLoS Pathog. 2008 Jun 13; 4(6):e1000084.
[PLoS Pathog. 2008]Blood. 2007 Aug 1; 110(3):1036-42.
[Blood. 2007]PLoS Med. 2006 Dec; 3(12):e528.
[PLoS Med. 2006]PLoS Med. 2006 Dec; 3(12):e528.
[PLoS Med. 2006]J Cell Biol. 2006 Mar 13; 172(6):899-908.
[J Cell Biol. 2006]Blood. 2007 Aug 1; 110(3):1036-42.
[Blood. 2007]Mol Microbiol. 2006 Feb; 59(3):779-94.
[Mol Microbiol. 2006]Nature. 2000 Aug 31; 406(6799):1001-5.
[Nature. 2000]J Cell Biol. 1994 Feb; 124(4):449-62.
[J Cell Biol. 1994]EMBO J. 2000 Jul 17; 19(14):3556-64.
[EMBO J. 2000]Science. 1997 May 16; 276(5315):1122-5.
[Science. 1997]Blood. 2004 Mar 1; 103(5):1920-8.
[Blood. 2004]PLoS Pathog. 2008 Jun 13; 4(6):e1000084.
[PLoS Pathog. 2008]Exp Parasitol. 2007 Sep; 117(1):87-92.
[Exp Parasitol. 2007]Nucleic Acids Res. 2003 Jan 1; 31(1):212-5.
[Nucleic Acids Res. 2003]Genome Biol. 2003; 4(2):R9.
[Genome Biol. 2003]Genome Biol. 2007; 8(7):R134.
[Genome Biol. 2007]Mol Biochem Parasitol. 2006 Aug; 148(2):144-60.
[Mol Biochem Parasitol. 2006]Nature. 2002 Oct 3; 419(6906):498-511.
[Nature. 2002]Nat Genet. 2007 Jan; 39(1):120-5.
[Nat Genet. 2007]Nat Genet. 2007 Jan; 39(1):113-9.
[Nat Genet. 2007]Genome Biol. 2003; 4(2):R9.
[Genome Biol. 2003]Nucleic Acids Res. 2002 Feb 15; 30(4):e15.
[Nucleic Acids Res. 2002]Biotechnology (N Y). 1993 Sep; 11(9):1026-30.
[Biotechnology (N Y). 1993]Proc Natl Acad Sci U S A. 2005 Nov 8; 102(45):16391-6.
[Proc Natl Acad Sci U S A. 2005]EMBO J. 2000 Jul 17; 19(14):3556-64.
[EMBO J. 2000]EMBO J. 2000 Jul 17; 19(14):3556-64.
[EMBO J. 2000]J Cell Biol. 1995 Mar; 128(5):779-92.
[J Cell Biol. 1995]EMBO J. 2000 Jul 17; 19(14):3556-64.
[EMBO J. 2000]EMBO J. 2000 Jul 17; 19(14):3556-64.
[EMBO J. 2000]J Biol Chem. 2003 Nov 28; 278(48):48413-21.
[J Biol Chem. 2003]EMBO J. 2000 Jul 17; 19(14):3556-64.
[EMBO J. 2000]PLoS Med. 2006 Dec; 3(12):e528.
[PLoS Med. 2006]EMBO J. 2000 Jul 17; 19(14):3556-64.
[EMBO J. 2000]